Directorate Change

1 Jun 2007 10:00

Plethora Solutions Holdings PLC01 June 2007 Plethora Solutions PLC DIRECTORATE CHANGE Plethora Solutions Holdings PLC ("Plethora" or the "Company", AIM: PLE), thespecialist developer of products for the treatment of urological disorders, ispleased to announce the appointment of Mark Docherty, 43, as a Non-ExecutiveDirector with immediate effect. He is currently a Director of Merlin BiosciencesLimited, a European venture capital firm specialising in investments in lifesciences. At the same time Professor Sir Christopher Evans, founder and chairman of MerlinBiosciences Limited, is stepping down as a Non-Executive Director. Stuart Wallis, Chairman of Plethora commented: "We welcome Mark to the Board of Plethora and would like to thank SirChristopher for his invaluable contribution to, and support of, Plethora fromits inception" Directorships/partnerships or other business interests held by Mark Dochertyduring the past five years: Current Directorships Merlin Investee CompaniesDecon Sciences Limited, Onyvax Limited, ReNeuron Group plc, ReNeuron Limited,ReNeuron (UK) Limited, ReNeuron Holdings Limited Merlin Group CompaniesMerlin Asset Management Limited, Merlin Limited, Merlin General Partner IIILimited, Merlin (Scotland) GP Limited, DevRx Limited (Dormant), MerlinBioscience Limited (Dormant), Merlin Biomed Limited (Dormant), MerlinBiosciences Limited, Merlin Ventures Limited Past Directorships EpiCept Corp, Intercytex Group plc, Cambridge Biotechnology Limited, MerlinEquity Limited, Intercytex Limited, Ashridge Gate Management Limited, BiowisdomLimited, KinderTec Limited, Centre for Nutritional Medicine Limited. In accordance with Schedule Two paragraph (g) of the AIM rules, there are noadditional disclosures to be made. For further information contact: Plethora Solutions Tel: 020 7269 8630Steven Powell City/Financial Enquiries Tel: 020 7379 5151MaitlandBrian Hudspith/Liz Morley Scientific/Trade Press Enquiries Tel: 020 7861 3838De Facto CommunicationsRichard Anderson About Plethora Solutions: Plethora is focused on the development and marketing of products for thetreatment of urological disorders. The Company has products in clinicaldevelopment for the treatment of overactive bladder, stress urinaryincontinence, interstitial cystitis, gynaecological pain and prematureejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based TimmMedical Technologies Inc which markets the ErecAid(R) and Rigiscan(R) productsfor the treatment of erectile dysfunction (ED) to urology clinics through aUS-based specialty sales team. Most recently, the ErecAid has been found to beeffective for men that fail Medical Management and for men recovering fromprostatectomy The Company is headquartered in the UK and is listed on the LondonStock Exchange (AIM:PLE) Further information is available atwww.plethorasolutions.co.uk This information is provided by RNS The company news service from the London Stock Exchange